Skip to main content

6 Result(s)

within Kai Markus Schneider Remove this filter

and

  1. No Access

    Article

    Personalisierte Therapie der metabolisch assoziierten Fettlebererkrankung

    Die metabolisch assoziierte Fettlebererkrankung (MAFLD) ist eine häufige Lebererkrankung, die bisher unter der Bezeichnung nichtalkoholische Fettlebererkrankung (NAFLD) bekannt ist. Die Umbenennung in MAFLD is...

    Jan Clusmann, Kai Markus Schneider, Paul-Henry Koop… in Die Gastroenterologie (2023)

  2. Article

    Open Access

    Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis

    Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by chronic inflammation and progressive fibrosis of the biliary tree. The majority of PSC patients suffer from concomit...

    Wenfang Gui, Mikal Jacob Hole, Antonio Molinaro, Karolina Edlund… in Nature Communications (2023)

    Download PDF (7768 KB) View Article

  3. Article

    Open Access

    Imbalanced gut microbiota fuels hepatocellular carcinoma development by sha** the hepatic inflammatory microenvironment

    Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, and therapeutic options for advanced HCC are limited. Here, we observe that intestinal dysbiosis affects antitumor immune s...

    Kai Markus Schneider, Antje Mohs, Wenfang Gui, Eric J. C. Galvez… in Nature Communications (2022)

    Download PDF (5506 KB) View Article

  4. No Access

    Article

    β-Hydroxybutyrate suppresses colorectal cancer

    Colorectal cancer (CRC) is among the most frequent forms of cancer, and new strategies for its prevention and therapy are urgently needed1. Here we identify a metabolite signalling pathway that provides actionabl...

    Oxana Dmitrieva-Posocco, Andrea C. Wong, Patrick Lundgren, Aleksandra M. Golos… in Nature (2022)

  5. No Access

    Article

    Aging disrupts circadian gene regulation and function in macrophages

    Aging is characterized by an increased vulnerability to infection and the development of inflammatory diseases, such as atherosclerosis, frailty, cancer and neurodegeneration. Here, we find that aging is assoc...

    Eran Blacher, Connie Tsai, Lev Litichevskiy, Zohar Shipony… in Nature Immunology (2022)

  6. No Access

    Article

    Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling

    Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology for which there are no approved therapeutic options. Patients with PSC display changes in gut microbiota and in ...

    Kai Markus Schneider, Lena Susanna Candels, Johannes R. Hov… in Nature Metabolism (2021)